<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01735097</url>
  </required_header>
  <id_info>
    <org_study_id>BSMMU-002-CT</org_study_id>
    <nct_id>NCT01735097</nct_id>
  </id_info>
  <brief_title>Effect of Nigella Sativa in the Treatment of Palmer Arsenical Keratosis</brief_title>
  <official_title>A Double-blind, Randomized, Placebo-controlled Trial of Nigella Sativa in the Treatment of Palmer Arsenical Keratosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Daily intake of Nigella sativa for 12 weeks is effective in the treatment of palmer arsenical
      keratosis
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Depending on inclusion and exclusion criteria total 40 patients of palmer arsenical keratosis
      patients (both male and female; age range 18- 60 years) will be recruited from an arsenic
      affected area. Study population will be divided randomly into two equal groups: one group
      will receive vitamin E capsules (200 mg) plus placebo and another group will receive vitamin
      E capsule plus N. sativa capsules (500 mg) twice daily for 12 weeks. Drinking water (50 mL)
      and urine (50 mL) samples will be collected before starting the study and estimate the amount
      of total arsenic in order to confirm the diagnosis. Nail (approx. 1 g) and blood (5 mL)
      samples will be collected both before and completion of the study to see the efficacy and
      safety of the drug. Clinical examinations will be done at regular interval (two weeks).
      Clinical features and adverse effects will be recorded using a structured data collection
      sheet. Plasma cholesterol, vitamin E, and total antioxidant, serum transaminase, billirubin,
      creatinine levels and arsenic level in nail will be measured to evaluate the effectiveness of
      N. sativa on palmer arsenical keratosis patients
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2013</start_date>
  <completion_date type="Actual">November 2013</completion_date>
  <primary_completion_date type="Actual">November 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical improvement of signs and symptoms of palmer arsenical keratosis</measure>
    <time_frame>up to 12 weeks</time_frame>
    <description>Signs and symptoms of palmer arsenical keratosis will be examined by one trained doctor at the temporary arsenic camp at regular interval (2 weeks). Another doctor will note the findings of the patient in the data collection sheet without informing the previous data to the former doctor.
Signs and symptoms of moderate arsenical keratosis will be assessed by estimating the number and size of keratotic lesions and expressed into scoring.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Arsenic level in nails</measure>
    <time_frame>0 week (baseline), 12 weeks (end)</time_frame>
    <description>Amount of arsenic in nails will be estimated by Atomic Fluorescence spectrometry (AFS) both before and after completion of treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Estimation of serum vitamin E levels</measure>
    <time_frame>0 week (baseline), 12 weeks (end)</time_frame>
    <description>To see any change in the concentration of plasma vitamin E levels after use of N.sativa capsules. This parameter will be estimated by spectrophotometric method.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Estimation of serum total cholesterol levels</measure>
    <time_frame>0 week (baseline), 12 weeks (end)</time_frame>
    <description>To see any change in the concentration of serum cholesterol levels after use of N. sativa. This parameter will be estimated by spectrophotometric method.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Liver function</measure>
    <time_frame>0 week (baseline), 12 weeks (end)</time_frame>
    <description>To see any change in the concentration of serum bilirubin, transaminase levels after use of N. sativa. These parameters will be estimated by spectrophotometric method.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Renal function</measure>
    <time_frame>0 week (baseline), 12 weeks (end)</time_frame>
    <description>To see any change in the concentration of blood urea and serum creatinine levels after use of N. sativa. These parameters will be estimated by spectrophotometric method.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Arsenical Keratosis</condition>
  <arm_group>
    <arm_group_label>Arsenical keratosis (Study)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Vitamin E (200 mg, soft capsule) plus Nigella sativa (500 mg, soft capsule) twice daily, orally for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arsenical keratosis (Control)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Vitamin E (200 mg, soft capsule) plus Placebo (refined oil in soft capsule with same size and color as that contains N sativa) twice daily, orally for 12 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Vitamin E</intervention_name>
    <description>Vitamin E (200 mg, soft capsule)</description>
    <arm_group_label>Arsenical keratosis (Study)</arm_group_label>
    <arm_group_label>Arsenical keratosis (Control)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Nigella sativa</intervention_name>
    <description>Nigella sativa (200 mg, soft capsule)</description>
    <arm_group_label>Arsenical keratosis (Study)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo (refined oil in soft capsule with same color and size like that contains N. sativa)</description>
    <arm_group_label>Arsenical keratosis (Control)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Moderate palmer arsenical keratosis

          -  Patient drinking arsenic contaminated water (more than 0.05 mg/L) for more than six
             months

          -  Subjects those voluntarily agree to participate

        Exclusion Criteria:

          -  Patient received treatment of arsenicosis for the last three months

          -  Pregnancy

          -  Lactating mother

          -  Eczema

          -  Psoriasis

          -  Contact dermatitis

          -  Tuberculosis

          -  Diabetes mellitus

          -  Patients with hepatic and renal impairment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mir Misbahuddin, MBBS, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>BSMMU</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Pharmacology, Bangabandhu Sheikh Mujib Medical University</name>
      <address>
        <city>Dhaka</city>
        <country>Bangladesh</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Bangladesh</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 15, 2012</study_first_submitted>
  <study_first_submitted_qc>November 27, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 28, 2012</study_first_posted>
  <last_update_submitted>May 2, 2014</last_update_submitted>
  <last_update_submitted_qc>May 2, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 5, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh</investigator_affiliation>
    <investigator_full_name>Prof. Mir Misbahuddin</investigator_full_name>
    <investigator_title>Prof. and Chairman, Department of Pharmacology</investigator_title>
  </responsible_party>
  <keyword>Arsenic</keyword>
  <keyword>Keratosis</keyword>
  <keyword>Nigella sativa</keyword>
  <keyword>Palm</keyword>
  <keyword>Vitamin E</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Keratosis</mesh_term>
    <mesh_term>Keratosis, Actinic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamins</mesh_term>
    <mesh_term>Vitamin E</mesh_term>
    <mesh_term>Tocopherols</mesh_term>
    <mesh_term>Tocotrienols</mesh_term>
    <mesh_term>alpha-Tocopherol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

